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Abstract
In spite of the huge achievements made in the early detection of uterine cervix cancer, this disease remains one of the most widespread human 
malignancies throughout the world.  Nowadays, there is a tendency of cervical cancer to affect the youth population.  Early metastasizing is a 
critical point in evolution of this disease.  Lymphatic vessels (LV) represents the primary route of cancer cells spreading towards the distant sites. 
That is why understanding of new lymphatics recruitment by the tumor, at molecular level, could be a potent support in solving of metastasizing. 
VEGFR-3 is a tyrosine-kinase receptor, specific for lymphatic endothelial cells, that being activated provides their proliferation, surviving and 
migration.  It has been demonstrated that VEGF-R3 mediates invasion activity of tumor cells into surrounding stroma and vascular structures. 
The aim of this research was to study the importance of VEGFR-3 in cervical carcinogenesis.  Material and methods: We studied biological material, 
taken by targeted biopsy and conization, from women with detectable cervical lesions.  Detection VEGFR-3 was made using monoclonal antibody 
anti VEGF-R3 through Avidin-Biotin working system, LSAB+ technique.  Lymphatic microvascular density was assessed by podoplanin labeling, 
using anti D2-40.  A statistical analysis was made with SPSS 13.0.  Results: We obtained VEGFR-3 expression in LV, blood vessels, tumor mass 
and stromal cells.  The highest density of VEGFR-3 + LV was in CIN III with gradually decreasing in invasive stages.  In invasive carcinoma we 
obtained statistically significant correlation between tumor VEGFR-3 expression and vascular invasion.  Conclusions: VEGFR-3 is not specific 
for lymphatic endothelium.  It can not be used for alone lymphatic microvascular density assessing.  It is actively involved in vascular invasion.
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Роль рецептора сосудистого эндотелиального фактора роста (VEGFR-3) в процессе канцерогенеза шейки матки
Несмотря на огромный успех, достигнутый в выявление рака шейки матки (РШМ) на ранних стадиях развития, данное 
заболевание остается одной из самых часто встречающихся злокачественных новообразований во всем мире.  На сегодняшний 
день наблюдается тенденция омоложения РШМ.  Раннее метастазирование является ключевым моментом в эволюции заболевания. 
Лимфатические сосуды представляют собой первичный путь распространения опухолевых клеток.  В связи с этим, понимание 
механизмов образования лимфатических сосудов на молекулярном уровне, может помочь решить эту проблему.  VEGFR-3 является 
тирозин-киназным рецептором.  Он находится на поверхности лимфатических эндотелиальных клеток, при активации которого 
происходит их пролиферация, миграция и выживание.  Было доказано, что VEGFR-3 регулирует инвазию раковых клеток в строму 
и сосуды.  Цель работы: изучить роль VEGFR-3 в канцерогенезе РШМ.  Материал и методы: был изучен биологический материал, 
полученный посредством прицельных биопсий и конизаций у пациенток с макроскопически выявленным поражением шейки матки. 
Для определения VEGFR-3 была использована система Avidin-Biotin, техника LSAB+, с применением первичного антитела анти VEGFR-3. 
Для определения лимфатических сосудов были использованы моноклональные антитела анти D2-40.  Статистический анализ данных 
был произведен при помощи SPSS 13.0.  Результаты: мы выявили экспрессию VEGFR-3 не только в лимфатических сосудах, а также в 
кровеносных сосудах, в опухолевой массе и клетках стромы.  Наибольшая плотность лимфатических сосудов была определена на стадии 
CIN III (интраэпителиальная цервикальная неоплазия), с последующим прогрессивным уменьшением.  На стадии инвазивного рака 
мы получили статистически значимую корреляцию между интенсивностью экспрессии VEGFR-3 опухолью и сосудистой инвазией, 
а также между интенсивностью экспрессии VEGFR-3 опухолью и внутрисосудистыми опухолевыми эмболами.  Выводы: VEGFR-3 не 
является специфическим маркером для лимфатического эндотелия.  Данный маркер не может использоваться самостоятельно для 
определения лимфатической микрососудистой плотности.  VEGFR-3 активно вовлечен в процесс сосудистой инвазии.
Ключевые слова: лимфатические сосуды, рак шейки матки, лимфатические эндотелиальные клетки, сосудистая инвазия, VEGFR-3, D2-40.
Introduction
The role of HPV in cervical carcinogenesis is well-establi-
shed and documented.  This fact allowed the researchers to 
perform different strategies focused mainly on the prevention 
of this type of neoplasia, in contrast with other tumor diseases. 
As a result, both the morbidity and the mortality drastically 
decreased.  Despite the facts named-above, cervical cancer 
remains one of the most frequent tumors, especially in those 
countries where the screening methods are not set enough.
There is a critical moment, related to its size, till which 
the newly-grown tumor can develop without any blood sup-
ply support.  Overcoming this moment does not disturb the 
continuing development of the neoplasm.  It happens due to 
a secretion of a wide variety of active substances (growth fac-
tors, cytokines), by the tumor cells and the stromal elements, 
which lead to the development of new blood vessels from 
the preexisting ones.  This phenomenon, called angiogenesis 
(AG), not only provides the tumor with necessary nutrients 
and gasses, but also represents a gate for the neoplastic cells 
spread to the distant sites.  A lot of varieties of human tumors, 
in parallel with blood vessels, co-opt the new lymphatic ves-
sels, also, through lymphangiogenesis (LAG).  The lymphatic 
vasculature, as well as the blood network, plays a crucial role 
in the tumor cells spreading.  The lymphatic vessels represent 
the main ways which through the regional lymph nodes are 
metastaticaly affected.  The importance of tumoral LAG beco-
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mes clear in the light of the effects which consequently appear 
after metastatic damage of the regional lymph nodes.  Their 
affection hardly influences clinico-pathologic parameters, 
such as: tumor grading, therapeutic management, surviving.
The most effective mitogens for endothelial cells are 
represented by a family of glycoproteins called VEGF (Vas-
cular Endothelial Growth Factor), which includes VEGF-A, 
VEGF-B, VEGF-C, VEGF-D and PlGF (Platelet Derived 
Growth Factor).  These growth factors are key regulators of 
vasculogenesis, AG and LAG, and promote their specific 
effect via transmembrane tyrosin-kinase receptors: VEGFR-1, 
VEGFR-2 and VEGFR-3. VEGF-A and VEGF-B are specific 
ligands for VEGFR-2 and VEGFR-1, and promote AG. VEGF-
C and VEGF-D are ligands for VEGFR-3 and promote LAG. 
VEGFR-2 can bind not only proangiogenic mediators, but 
also VEGF-C (in it’s fully enzyme processed variant), whereas 
VEGFR-3 has affinity only for growth factors which induce 
lymphangiogenic signals.
During the early embryonic development VEGFR-3 is 
expressed in blood endothelial cells (BEC), and represents 
a key regulator of primary capillary plexus formation [5]. 
Contact with vascular smooth muscle cells (vSMC) downre-
gulates the VEGFR-3 in endothelial cells [17].  Once the LAG 
begins, the expression of VEGFR-3 gradually decreases in 
blood vessels, and eventually becomes restricted to the lym-
phatic vessels and fenestrated blood capillaries.  VEGFR-3 is 
responsible for the proliferation, migration and organization 
of new lymphatics.  Continues ligand-induced activation of 
newly-formed lymphatic endothelial cells (LEC) by VEGFR-3 
provides their surviving during embryogenesis and postna-
tal period (first two weeks), after which lymphatic vessels 
become independent of VEGFR-3 [1].  In adults, VEGFR-3 
remains expressed in lymphatic vessels devoid of vascular 
smooth muscle cells.  This finding suggests that VEGFR-3 is 
important in nascent blood vessels and is redundant when 
vessels are mature. VEGFR-3 gene-targeted mice have severe 
heart failure with embryonic mortality at E9. 5 (E-embryonic 
day) due to catastrophic defects in remodeling of the primary 
venous plexus.  Early embryonic lethality of the VEGFR-3 
null-mice hampered the assessment of the importance of this 
growth factor receptor in LAG, because these mice die before 
the emergence of the lymphatic vessels [2].  However, the 
identification of missense mutations in VEGFR-3 in patients 
with hereditary lymphedema has provided the support of this 
gene in lymphatic development [4].
It is widely accepted that VEGF-C/VEGFR-3 axis plays 
the crucial role in LAG.  Skobe M. et al. [12] described a 
correlation between VEGF-C levels and VEGFR-3 amount 
in intratumoral area of breast cancer.  Moreover, they showed 
dependence between VEGFR-3 phosphorylation activity, 
induced by VEGF-C overexpression, and regional lymph 
nodes metastases.  In animal models, the induction of LAG 
by VEGF-C/VEGFR-3 axis increased tumor metastases via 
the lymphatic system [13].
In addition to its expression on LEC there are a lot of 
papers which describe the expression of VEGFR-3 in vas-
cular tumors [10], lymphangiomas [9], Kaposhi sarcoma, 
myoepithelial cells in mammary glands [3], neoplastic cells 
in a wide variety of solid human tumors, monocytes, macro-
phages, dendritic cells, blood endothelial cells (BEC).  These 
data have shown that VEGFR-3 expression is not restricted to 
endothelial cells.  There is a growing body of evidences that 
VEGFR-3 expression and function correlate with metastatic 
activity of cancer cells in solid tumors.
The aim of this study was to elucidate the features of VE-
GFR-3 expression in all stages of the uterine cervix neoplasia 
progression.
Material and methods
We studied biological material taken by targeted biopsy 
and conization, from women with macroscopically detec-
table lesions of the uterine cervix area, at the Institute of 
Oncology from 2006 to 2009.  For each case we made routine 
histological staining with hematoxilin and eosin, in order to 
establish the morphological diagnosis and tumor grading, as 
well.  As a result, we obtained following lesions: squamous 
cell metaplasia – 12 cases (n = 12), CIN I (n = 8), CIN II 
(CIN II - 6), CIN III (n = 24), microinvasive carcinoma (n = 
16) and invasive squamous cell carcinoma (n = 26). Additi-
onal 5 µm thick sections, for each case, we stained with anti 
VEGFR-3. Immunohistochemical staining was performed 
in accordance with LSAB+ technique, using Avidin-Biotin 
working system.  As a primary monoclonal antibody we used 
anti VEGFR-3 (Santa Cruz, US Carpinteria), 1:200.  After 
antigen retrieval, performed by heating with microwave oven 
in retrieval solution pH6 (Dako Cytomation), we incubated 
the specimens with primary antibody for 30 minutes. Incuba-
tion time for both, secondary and tertiary antibodies was 15 
minutes.  After applying each antibody, we rinsed specimens 
carefully with PBS buffer phosphate solution pH 7.2. Nuclei 
counterstaining we made with Lille modified hematoxiline. 
For lymphatic microvascular density assessment, we used 
D2-40 immunolabeling.  Staining with D2-40 (clone D2-40, 
Dako Cytomation, Denmark) was made on additional sec-
tions, for each case, using the same technique and working 
system.  The entire immunohistochemical technique was 
performed by autostainer (Dako Cytomation).  Images were 
taken with Nikon Eclipse (E600) photo camera.  Counting of 
immunolabeled lymphatic vessels was done using the method 
proposed by Van der Auwera [15]. Evaluation of the intensity 
expression of VEGFR-3 was made using a scale with 4 values: 
0 – absence of expression; 1- low intensity; 2 – intermediate 
expression; 3 – high intensity.  Statistical analyses of obtained 
data we made with SPSS 13.0, using Paired-Samples T Test 
and bivariate correlation, where p < 0.05 was considered as 
statistically significant.
Results
Squamous metaplasia: D2-40 positive lymphatic vessels (LV) 
were large, with wide lumen, placed in deep stroma. We found 
VEGFR-3+ LV and blood vessels (fig.1).  In all cases, the squamo-
us stratified epithelium was negative for VEGFR-3, whereas the 
basal layer was positive, and considered as inner positive control. 
VEGFR-3 positive cells were not present in stroma.
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CIN I and II: The shape, localization and size of LV were not 
significantly different in comparison with squamous metaplasia. 
On the other hand, in CIN II stage, small vascular structures 
appeared with VEGFR-3 positive endothelium.  Among these 
vessels not only LV but also blood vessels were present, deducti-
on made on the presence of erythrocytes into their lumen.  The 
intensity of VEGFR-3 expression by the neoplastic epithelium 
ranged between 0 and 2.  We also noticed the presence of few 
cellular elements in stroma, positive for VEGFR-3.
CIN III: LV were present not only in deep stroma, but 
also in lamina propria, just in front of the epithelial mass 
(fig.2). Almost all vascular structures from superficial lamina 
were small, flattened, elongated, with narrow lumen.  Many 
of VEGFR-3+ vessels were blood vascular structures.  We 
found a discontinuous pattern of D2-40 expression by the 
basal layer of stratified epithelium.  Epithelial expression of 
VEGFR-3 was present in 71.2% (19 cases).  The mean value 
of the expression intensity was 2.
Microinvasive carcinoma: The density of LV was lower than 
in CIN III.  Morphological features of LV were approximately 
the same like in severe intraepithelial neoplasia.  A lot of ves-
sels were placed in immediate vicinity of invasive front.  We 
noticed that mainly small vessels express VEGFR-3.  Inside 
the tumor mass expression was heterogeneous.  Usually, the 
central part of the tumor had more intensive expression than 
the invasive front (fig.3).  The number of the stromal cells, 
positive to VEGFR-3 was significantly higher than in previous 
stages of uterine neoplasia progression.
Invasive carcinoma: We found LV not only in the stroma, but 
also inside the tumor mass. Both vascular densities, detected with 
D2-40 and VEGFR-3 (fig.4), were much higher in peritumoral 
area than in intratumoral.  LV from the peritumoral stroma 
were larger and perfusable, in comparison with those, placed 
intratumorally.  Vascular invasion was detected in 15 of 26 cases 
(57.7%) of invasive carcinoma.  Intratumoral LV were detected 
in 25 cases (96.1%).  In 3 cases (11.5%) we found intratumoral 
LV with emboli (fig.5), and in all these specimens peritumoral 
LV were also invaded.  Peritumoral invaded LV were large, with 
well-distinguished lumen (fig.6). VEGFR-3 expression in the 
tumor mass had the same features with expression in micro-
invasive carcinoma (fig.7).  In 5 cases – 19.23% - we detected 
diffuse, strong VEGFR-3 expression in tumor mass (fig.8).  The 
intensity of VEGFR-3 expression by the vascular emboli was 
always higher than the expression by the tumor mass.  We also 
found, statistically significant correlation (p = 0.037) between 
tumor expression of VEGFR-3 and vascular invasion.  Numerous 
















































D2-40 9.2 10.5 13.8 18.71 16 8.5
VEGFR-3 (LV) 3 3.6 4.2 8.2 8 4.6
VEGFR-3 (general  
vascular density) 1.6 7 9.4 21 17.3 12.6
Discussions
In this study, using monoclonal antibody for VEGFR-3, we 
demonstrated that this molecular agent is necessary not only 
for LV formation, but also has a wider spectrum of activity 
in cervical carcinogenesis.
Initially, it was described as a tyrosine-kinase receptor that 
binds specifically vascular endothelial growth factors, which 
enhance the mitogenic activity of lymphatic endothelial cells, 
VEGF-C and VEGF-D [7].  Further investigations showed 
that VEGFR-3 is acquired for blood vessels formation, as 
well [6].  Moreover, using this marker for tumor-induced 
lymphangiogenesis studying, a lot of researchers revealed its 
affinity for malignant cells in wide spectrum of solid human 
cancers.  Many consequent molecular investigations showed 
that intensity of VEGFR-3 expression correlates with aggres-
sive metastatic behavior of the tumor.
Podoplanin is a transmembranar glycoprotein, expressed 
in podocytes, fibroblasts, striated muscles, alveolar cells type 
I, lymphatic endothelial cells.  Commercially available marker 
for podoplanin – D2-40 – allows identifying of fixation resis-
tant epitope in formalin fixed and paraffin embedded sections, 
and seems to be the most specific lymphatic marker [14].
 Each tumor produces a wide variety of molecular factors 
that provide the formation of own tumor vascular supply. 
Gradually, during the tumor progression, in this process 
stromal cellular elements are actively involved.  As a result, 
the density of newly-formed blood and lymphatic vessels 
increases.  In this study, we obtained a linear increasing of 
D2-40+ LV till CIN III stage. Beginning with microinvasive 
carcinoma stage, LV density progressively decreased.  Our 
data are consistent with results of other authors [16].  This 
phenomenon could be explained by the fact that tumor, in 
its invasive stage of progression, destroys vessels rather than 
induces formation of others. It is well known that VEGF-C 
overexpression activates VEGFR-3.  We have reported that 
intensity of VEGF-C expression correlates with the stage 
of uterine cervix neoplasia progression, being the highest 
in the invasive carcinoma stage [8].  In this case appears 
one question: if VEGF-C overexpression is the highest in 
invasive carcinoma, why the density of VEGFR-3 LV is so 
low in the same stage?  We think that there is nothing sur-
prising in this situation, and explain this high discrepancy 
between VEGFR-3 and VEGF-C expression by the fact that 
receptor is hidden by its ligand.
Expression of VEGFR-3 in blood endothelial cells was 
often previously reported.  Moreover, it has been suggested 
that this lymphatic specific receptor, is necessary for tumor-
induced angiogenesis.  It has been shown that VEGFR-3 has 
a crucial role in early blood vessels formation. It has been 
suggested that tumoral angiogenesis repeat the same stages, 
and each stage is regulated by the same molecular players, em-
bryonic angiogenesis passes through.  In this research, almost 
all blood vessels were small, an indication that these vessels 
were young.  However, we can not explain the positive reaction 
of endothelial cells from large blood vessels.  Expression of 
VEGFR-3 in blood endothelial cells makes it improperly for 
lymphatic microvascullar density assessing.
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At the moment there are some strong debates about the 
expression of VEGFR-3 in tumor mass.  Tatiana Petrova et 
al. [11], consider that this receptor’s expression is restricted 
in solid tumors to lymphatic and blood endothelium.  On 
the other hand, there is an increasing body of evidences 
about its expression not only by the tumor mass, but also by 
the stromal cells.  Our data are consistent with the second 
opinion.  Tumoral expression of VEGFR-3 correlated with 
vascular invasion, in our study, whereas it has been proved 
that VEGFR-3 together with VEGF-C, increase the motility 
of neoplastic cells and facilitate vascular penetration.
Concluding remarks
During the cervical carcinogenesis, VEGFR-3 plays a 
multifactor role.  It is involved in formation of blood and lym-
phatic tumor-derived vasculature.  This molecular agent has a 
highly-expressed heterotopic affinity.  Hiding of the receptor 
by its ligand and concomitant expression by the lymphatic 
and blood endothelial cells makes impossible the studying 
of lymphatic microvascular density, using only VRGFR-3. 
It is needed to duplicate the procedure with D2-40. Positive 
immunoreactivity of all intravascular emboli, corroborated 
with statistically significant correlation between tumor expre-
ssion of the marker and vascular invasion, strongly indicates 
the crucial importance of VEGFR-3 in metastasizing.  Taken 
together, all these findings show that targeted anti VEGFR-3 
blocking could a potent therapeutic strategy against tumor 
progression, especially vascular invasion and metastases, 
during the cervical carcinogenesis.
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